• Verapamil: Identity, Mechanism, and Evidence Scope

  2026-10-14

  APExBIO describes Verapamil ((±)-Verapamil), SKU BA6564, as a voltage-dependent calcium channel blocker and first-generation P-glycoprotein inhibitor. The available documentation supports a product-identity and mechanism overview, but it does not provide an identity-matched research paper, effect estimates, model details, or evidence for specialized applications such as hypoxia-driven inflammation.

• GLP-1 (9-36) Amide: Evidence and Limits

  2026-10-14

  Research on GLP-1 receptor cross-talk shows that glucagon-related ligands can produce noncanonical signaling at the GLP-1 receptor, but the cited study used exendin(9-39), not GLP-1 (9-36) amide. Its findings therefore inform receptor-selectivity questions without directly establishing the activity or applicability of the supplied peptide.

• Reassessing v-Agatoxin Calcium-Channel Selectivity

  2026-10-13

  Sidach and Mintz found that v-Aga-IVA remains a high-affinity P-type calcium-channel blocker but can also inhibit N-type currents weakly, complicating toxin-based channel classification. The study does not directly test Isradipine, Dynacirc, or L-type channels.

• CENPI, Wnt/β-Catenin and Breast Cancer Progression

  2026-10-13

  A 2025 study links elevated centromere protein I (CENPI) with breast cancer progression and reports that CENPI-related phenotypes involve Wnt/β-catenin signaling. Its combination of patient-dataset analysis, cellular studies, xenograft models, transcriptomics and pathway-focused validation supports a preclinical mechanistic hypothesis, but limited human-tissue sampling and model dependence constrain clinical interpretation.

• Neuromedin S (rat): Identity and Evidence Scope

  2026-10-12

  Neuromedin S (rat), listed by APExBIO as SKU B5466, is a supplier-described endogenous peptide agonist associated with neuromedin U receptor signaling. The available product information supports a limited conceptual scope around GPCR/G protein signaling, energy homeostasis regulation, and stress response research, but no matched reference paper or product-specific outcome evidence was provided.

• GS-441524 Prodrug Evidence: What Is Still Unknown

  2026-10-12

  A January 2026 preclinical study traced conversion of the GS-441524 prodrug NGP-1 across gastrointestinal, hepatic, blood, and rat-model contexts. Its findings clarify disposition pathways, but they do not establish comparative antiviral efficacy, clinical pharmacokinetics, or safety in humans.

• 2'3'-cGAMP and Exosomal ENPP1: Evidence Gaps

  2026-10-11

  An evidence-focused interpretation of An et al. (2024) finds that tumor-derived exosomal ENPP1 is reported to hydrolyze both synthetic and cell-produced 2'3'-cGAMP, including cGAMP associated with LL-37. The findings broaden the proposed extracellular regulation of cGAS-STING signaling, but they do not establish universal kinetics, clinical relevance, or equivalence among cGAMP formulations.

• Triterpene Prodrug Enables Self-Boosted OSCC Therapy

  2026-10-10

  A 2024 ACS Applied Materials & Interfaces study reports a carrier-free triterpene prodrug that combines glycyrrhetinic acid, ginsenoside Rh2, and a reactive oxygen species-responsive linker for oral squamous cell carcinoma research. The design aims to couple tumor-associated uptake with feedback-enhanced drug release, although the evidence remains preclinical and does not establish clinical efficacy or translational safety.

• A40926: Evidence, Applications, and Limits

  2026-10-09

  A source-grounded overview of A40926 as a natural glycopeptide and dalbavancin precursor, with emphasis on its regulatory biology, conceptual uses in antibiotic research, published findings, evidence strength, and applicability limits.

• Caffeine: Mechanism, Evidence, and Research Limits

  2026-10-09

  Caffeine, also known as 1,3,7-trimethylpurine-2,6-dione, is primarily studied as an adenosine receptor antagonist. Supplier-reported findings support research questions involving cancer cell line inhibition and energy metabolism modulation, but the evidence does not establish clinical efficacy or an ALDH2 mechanism.

• 2-NBDG and HNF4A-AS1 in HCC Metabolism

  2026-10-08

  This overview places the 2-NBDG Glucose Uptake Assay Kit in the context of hepatocellular carcinoma metabolism research and evaluates what it can—and cannot—add to a 2024 study of HNF4A-AS1, lipid metabolism, ferroptosis, and sorafenib resistance. The study provides preclinical evidence for a lipid-centered mechanism but does not report 2-NBDG measurements or establish that altered glucose uptake drives treatment resistance. Fluorescent glucose uptake readouts may offer a complementary phenotype, provided they are interpreted as analogue uptake-associated signals rather than direct measurements of glucose flux or lipid metabolism.

• 3D Proteomics and Carboplatin Response in HGSOC

  2026-10-08

  A 2025 study compared whole-cell proteomes from two-dimensional and three-dimensional high-grade serous ovarian carcinoma models, quantifying 6,404 proteins and identifying 371 commonly altered proteins. Its findings indicate that culture dimensionality reshapes metabolism, membrane-associated proteins, and Carboplatin response, providing a stronger rationale for model selection in preclinical oncology research.

• Neuromedin S (rat): Product Overview

  2026-10-07

  Neuromedin S (rat), SKU B5466, is a supplier-described endogenous peptide agonist associated with neuromedin U receptor signaling. No matched paper evidence was supplied, so biological performance and assay suitability remain unverified.

• Separating Growth Arrest from Cell Death in Cancer

  2026-10-07

  Hannah Schwartz’s 2022 doctoral dissertation examines why conventional relative-viability measurements can obscure the distinct contributions of proliferation arrest and cell death. Its central contribution is a framework for interpreting anticancer drug responses as separable, time-dependent biological processes rather than as a single composite endpoint.

• 2'3'-cGAMP and the Next STING Frontier

  2026-10-06

  The next phase of cGAS-STING research will connect innate immune signaling with metabolic state. This thought-leadership analysis examines how 2'3'-cGAMP can serve as a defined STING-proximal research tool, while the 2025 D2HG biosensor study opens new questions about immune–metabolic feedback, translational biomarkers, and the limits of current evidence.

8453 records 2/564 page Previous Next 12345 下5页 Last page